- 86 percent of people with Parkinson's disease (PD) (n=113) taking the survey experience OFF time daily, and a majority report it has a significant impact on activities
- While three in four people with PD (78%) report that their current treatment plan is effective at limiting their PD symptoms, over half (56%) also say that they don't think their symptoms can improve beyond their current state
The survey was conducted by Ipsos, one of the largest market research and polling companies globally.
Key findings from the survey include:
People with PD and Care Partners Should Discuss OFF Time Symptoms with a Healthcare Provider
Among people with PD (n=113) taking the survey:
- 86 percent of these people with Parkinson's disease experience OFF time daily, and a majority report it has a significant impact on activities.
- While three in four people with PD (78%) report that their current treatment plan is effective at limiting their PD symptoms, over half (56%) also say that they don't think their symptoms can improve beyond their current state.
Among care partners (n=127) taking the survey:
- Care partners who took the survey are most likely to feel frustrated, anxious, and stressed when their loved ones with PD experience OFF time symptoms.
"The results of this survey reinforce that while numerous therapeutic options exist for our patients, these therapies may be under-utilized. We need to better explore what 'effective' means for each patient, and address what concerns may prevent them from seeking better symptom control," said
Misconceptions About Adjunctive Therapy
Among people with PD (n=113) taking the survey:
- Nearly all are willing to explore new treatment options (96%) and would ask their doctor about adjunctive therapies (94%).
- 72% of people with PD mistakenly believe that adding adjunctive therapy means their PD is progressing.
- Nearly half (49%) are unsure whether their current treatment plan is doing what it should, and 30% feel uninformed about additional treatment options.
Despite a majority of these people with Parkinson's disease and care partners being significantly impacted by OFF time, there is a general acceptance that the emergence of OFF time is part of the disease, and they may not be aware of the availability and use of adjunctive treatment options for use to address return of PD symptoms.
About the Survey Assessment: Impact of OFF Time on People with Parkinson's
Conducted by Ipsos, the Survey Assessment: Impact of OFF Time on People with Parkinson's
About Parkinson's Disease
Parkinson's disease (PD) is a chronic, progressive, and debilitating neurodegenerative disorder that affects approximately 1 million people in the
There is presently no cure for PD and management of the disease largely consists of the use of treatments that attempt to control PD symptoms. The current gold standard for treatment of PD symptoms is carbidopa/levodopa. While carbidopa/levodopa improves patients' PD symptoms, as the disease progresses, the effects of levodopa begin to wear off more quickly. OFF time is when PD symptoms—such as stiffness or tremors—return between regular doses of medication. OFF time can happen when carbidopa/levodopa is wearing off. The way OFF time affects people with PD and the symptoms they experience are unique.
Visit PMDAlliance.org to learn more.
Neurocrine and the Neurocrine logo are registered trademarks of
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from the Company's products and product candidates, the Company's plans to encourage awareness that may help address the needs of people living with PD, and the value that such awareness may bring to patients. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are: risks and uncertainties associated with the commercialization of the Company's products or product candidates; risks that the Company's products and/or product candidates may be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects or adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; risks associated with potential generic entrants for our products; risks associated with our dependence on third parties for manufacturing activities; risks that clinical development activities may not be completed on time or at all, or may be delayed for regulatory, manufacturing, COVID-19 or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the potential benefits of the agreements with our collaboration partners may never be realized; whether the survey findings represent the experiences of people living with PD; whether the Company can successfully encourage awareness that may help address the unmet needs of people living with PD; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2022. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof.
View original content to download multimedia:https://www.prnewswire.com/news-releases/parkinson--movement-disorder-pmd-alliance-and-neurocrine-biosciences-announce-new-survey-results-revealing-the-significant-impact-off-time-has-on-people-with-parkinsons-disease-and-their-care-partners-301621508.html
Neurocrine Biosciences: Media, Aimee White, 1-858-354-7865, firstname.lastname@example.org; Investors: Todd Tushla, 1-858-617-7143, email@example.com; PMD Alliance: Media, Debbie Rich, 1-800-256-0966, firstname.lastname@example.org